CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for LSL Pharma Group Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

LSL Pharma Group Inc
540, rue d'Avaugour, Office 1800
Phone: (450) 681-7744p:450 681-7744 BOUCHERVILLE, QC  J4B 0G6  Canada Ticker: LSLLSL
Business Summary
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specialized in the development, manufacturing and commercialization of sterile ophthalmic pharmaceuticals, as well as natural health products in solid and liquid dosage forms. It specializes in the manufacturing and marketing of natural health products (NHPs). The Company manufactures a range of NHPs in liquid, powder and capsule form, sold under its own brand or under private labels. Its manufacturing activities include blistering, encapsulation, sachet and jar filling. The Company also owns Dermolab Pharma Ltd., a contract manufacturing company that specializes in the development, manufacturing and packaging of liquid and semi-solid cosmetic, pharmaceutical and natural health products. It serves both the Canadian and international markets. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Virage Sante Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer FrancoisRoberge 2/22/2023 2/22/2023
Chief Financial Officer, Executive Vice President LucMainville 12/4/2023 2/22/2023
Vice President - Communications MarcBoudreault
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Laboratoire LSL 540, d'Avaugour Street #1800 Boucherville QC Canada
Virage Sant, Inc. 690, rue Perreault Lvis QC Canada
Demolab Pharma Ltee. 1421 Rue Nobel Sainte-Julie QC Canada
Steri-Med Pharma inc. 242 Rue Saint-Cyrille Upton QC Canada

Business Names
Business Name
BUX
Demolab Pharma Ltee.
ILE.H
4 additional Business Names available in full report.

General Information
Outstanding Shares: 115,532,676 (As of 9/30/2024)
Stock Exchange: CVE
Fax Number: (450) 681-8400


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025